Weighing up the pros and cons of disease modifying therapies

Lead researcher:: Dr Ana Manzano
Based at:: University of Leeds
MS Society funding:: £156,112
Status:

About the project

This project aims to help people with relapsing MS and their health care professionals to make the best decision about disease modifying therapies (DMT).

We now have 12 DMTs available for relapsing MS, and it can be very difficult for people to choose between them. Each DMT comes with its own pros and cons and some of the most effective treatments come with a higher risk of side effects.

Choosing the right DMT involves deciding what’s most important to us as an individual – our lives and the situations we’re in will change and dictate those choices.

That’s why Dr Manzano and her team are developing a survey where people can choose between lots of different treatment scenarios. This survey – being developed with the help of health care professionals and people with MS – will then be answered by over 500 people on the MS Register.

The survey aims to find out:

What aspects of a DMT are most important to people?
How do health care professionals communicate the side effects (e.g. nausea) and risks (e.g. a viral infection) of DMTs and how are they interpreted?
Could those risks and harms be communicated better, to make shared decision-making between people with MS and their neurologists easier?
Are people willing to ‘trade off’ potential risks and harms if it could improve the outcome of their health?

How will it help people with MS?

People with relapsing forms of MS need as much support as possible when choosing which DMT could be right for them. This decision should be shared with a neurologist.

Our research will improve our understanding of how people with MS weigh up the pros and cons of DMTs, and will help health care professionals to take those preferences into account when helping someone to choose a DMT.

The difference you can make

Helping to fund research like this will enable people with MS to have the opportunity to make informed decisions about their treatment and give greater certainty about their future.

The next research breakthrough is in reach

Your donation will help stop MS.

One-off donation

£30
£50
£100
Other Other amount

£

£30 could process one blood sample, giving researchers crucial information about genes and the immune system.

£50 could pay for an hour on a microscope, so scientists can study cells and tissue in greater detail and improve their understanding of the biology of MS.

£100 could pay for half an hour of MRI use, so researchers can monitor the success of clinical trials and understand MS in more detail.

Every penny you give really does take us a step closer to stopping MS. Your donation will make a difference.

Donate now

Monthly donation

£10
£20
£30
Other Other amount

£

£10 a month could pay for lab equipment like microscope slides to study the building blocks of MS

£20 a month could pay for lab equipment like petri dishes to grow bacteria important for studying genetics

£30 a month could process a blood sample to help us understand what causes MS, so we can stop it in its tracks

Your regular donation means we can keep funding world class MS research with confidence. Together we will stop MS.

Donate now

DMTs can reverse MS symptoms for some people

Disease modifying treatments (DMTs) may be able to reverse the symptoms caused by MS for some people with relapsing MS, according to new research published in the Journal of Neurology. This is the first study that has measured whether people’s long-term symptoms improve following treatment.

NICE approves ocrelizumab for early primary progressive MS

Today the National Institute for Health and Care Excellence (NICE) has approved ocrelizumab as the first treatment on the NHS for adults with early primary progressive MS.